Phenylbutazone is a potent analgesic agent currently employed in the treatment of various arthritic disorders (1) including acute gouty arthritis (1, 2) . It is generally agreed that administration of the drug to gouty subjects effects a sharp lowering of the serum urate level (1, 2). The mechanism by which this is accomplished is still obscure.
Phenylbutazone is a potent analgesic agent currently employed in the treatment of various arthritic disorders (1) including acute gouty arthritis (1, 2) . It is generally agreed that administration of the drug to gouty subjects effects a sharp lowering of the serum urate level (1, 2) . The mechanism by which this is accomplished is still obscure.
Evidence that phenylbutazone is a uricosuric drug which depresses tubular reabsorption of urate has been presented elsewhere (2, 3) . Further data are recorded here. These deal in greater detail with a) the acute and protracted effects of intravenous and oral phenylbutazone administration upon the renal clearance of urate and upon serum urate concentration; b) the effects of intravenously administered phenylbutazone upon the renal clearances of inulin, endogenous creatinine and PAH, the urinary excretion of sodium, potassium, chloride and inorganic phosphate, and upon TmpAH; and c) the effects of simultaneous administration of phenylbutazone and probenecid (Benemid) upon urinary urate excretion.
METHODS
The acute effects of intravenously administered phenylbutazone on the simultaneous renal clearances of urate, inulin, endogenous creatinine and p-aminohippurate, using techniques previously described (4) , were studied in ten gouty subjects in the intercritical phase of the disease. All abstained from meat and purine-rich food for three days prior to the study, which was started in the morning during the post-absorptive state. Liberal quantities of water were administered orally to maintain urine flows higher than 3 cc. per min. throughout the course of the acute clearance determinations. Following three 10 to 15 minute control urine collection periods, 1 or 2 Gm. of phenylbutazone (12 to 27 mg. per Kg. body weight) as the sodium salt in 20 per cent solution, further diluted in 100 cc. of normal saline solution, were administered intravenously at a rate of approximately 5 cc. per min. After the drug had been infused the bladder was washed with distilled water and urine was collected for six to eight 15 to 20 minute periods. Urine collections were continued every two hours during the day and every four hours during the night for an additional 18 to 20 hours in order to follow endogenous creatinine and urate clearances.
In two of the subjects, simultaneous inulin, p-aminohippurate and urate clearances were determined during slow phenylbutazone infusions so as to correlate the effects with rising plasma phenylbutazone concentrations. In three additional subjects this correlation was studied following rapid infusion of the drug. In two of the subjects the effect of phenylbutazone upon TmPAH was studied using standard techniques (5) .
The effects of intravenous administration of phenylbutazone on the renal excretion of sodium, potassium, chloride, inorganic phosphate and urate, and on the endogenous creatinine clearance, were studied in three hospitalized gouty subjects during a three-day control period, for two to four days of phenylbutazone administration, and three days thereafter. These subjects were maintained on a constant weighed diet and constant salt and water intake. The daily caloric intake was 1800 for two of the subjects and 1600 for the third. The protein intake was 60 Gm. per day for all, and the sodium chloride intake 3.5 Gm. per day for two, and 2.5 Gm. per day for one. Urine was obtained by spontaneous voiding, the collection periods being 9 a.m. to 3 p.m., 3 p.m. to 9 p.m. and 9 p.m. to 9 a.m. After three control period days 0.8 Gm. of phenylbutazone was administered intravenously in 0.2 per cent solution made up in 5 per cent glucose; this was delivered in divided doses of 0.2 Gm. each at 9 a.m. and 3 p.m. and 0.4 Gm. at 9 p.m. Blood samples were obtained just prior to each infusion.
The effect of orally administered phenylbutazone on the daily urinary output of urate was also studied in eight ambulatory subjects pursuing their normal daily activities. They received a 60 to 70 Gm. protein diet for 3 to 10 days preceding the control urine collections. After three 24-hour control urines and one or two control plasma urate determinations were obtained, 0.8 Gm. of phenylbutazone was administered daily in four divided doses for four to 1121 seven days. Plasma urate concentrations were determined periodically and urinary urate excretion measured daily throughout the period of study. In one of the subjects, T-1824 spaces were measured before and after 24, 48 and 96 hours of drug administration.
The effect of simultaneous administration of phenylbutazone and probenecid upon urinary urate excretion was studied in seven subjects.
The analytical methods for inulin, PAH, creatinine, sodium, potassium, chloride, inorganic phosphate and urate determinations in plasma and urine were those previously employed in the corresponding probenecid study (4) . All blood samples were heparinized and the analyses were performed on plasma. In order to ascertain whether phenylbutazone interfered with the method employed for urate determination in plasma and urine, the following studies were performed: 1) Serial dilutions of phenylbutazone (10 to 40 mg. per cc.) were added to standard urate solutions and to urine; 2) varying proportions of urine from a subject taking phenylbutazone were added to standard urate solutions and to urine from a subject not taking phenylbutazone; 3) equal portions of plasma from a subject receiving phenylbutazone were mixed, with plasma from a subject not receiving the drug; 4) all of the mixtures represented in 1, 2, and 3 were subjected to uricase digestion. In none of these studies was there evidence of interference with the recoveries of urate.
Plasma phenylbutazone concentrations were determined 
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The continued effects of a single intravenous injection of phenylbutazone on C urate and CCr for a period of 20 to 22 hours are summarized in Figure 1 and Table II . It is evident that the peak elevation in C urate/Ccr occurred during the first two to four hours after drug administration, ranging from + 64 per cent to + 390 per cent with a mean of + 176 per cent. A significant elevation of this ratio continued for the subsequent 20 to 22 hours, ranging from + 13 per cent to + 172 per cent and averaging + 87.8 per cent. This effect again was more marked with the higher drug dosages. In all of the subjects a significant fall in plasma urate concentration occurred by the end of 20 to 22 hours, the mean fall being from 9.0 mg. per cent to 6.9 mg. per cent (Table II) . The magnitude of this response could be correlated with the mean rise in C urate/Cor during this time interval. The effects of orally administered phenylbutazone, given in a daily dosage of 800 mg., upon the 24-hour urinary urate excretion and the plasma urate concentration are summarized in Table III . The mean control urinary urate excretion in the eight gouty patients studied ranged from 198 to 658 mg. per 24 hours. In four subjects, uricosuria appeared during the first day of drug administration, in two subjects on the second day, and in two subjects on the third day. The peak uricosuria occurred on the first day in one patient, on the second day in one, and on the fourth day in six. In all save one subject there was an overall increase in urinary urate excretion throughout the total period of medication, the mean increase ranging from + 23 per cent to + 168 per cent. The one subject who did not show a continued uricosuric response, Case R. R., had received phenylbutazone elsewhere for several months shortly before instituting the present study. In this subject, increased urinary urate excretion occurred on the first day of medication only, 632 mg. per 24 hours, as compared to a control value.of 534 mg. In spite of absence of any further uricosuric action of phenylbutazone, a plasma urate concentration of 4.6 mg, per cent was observed on the fourth day, the control value being 8.1 mg. per cent. In the three subjects given rapid intravenous infusions of Depression of the PAH clearance occurred in all subjects so studied, the mean control value of 495 cc. per min. falling to a mean minimum value of 326 cc. per min. (Table I ). Concomitant elevations of the filtration fraction, Cm./CpAx, occurred in all subjects. This effect upon CPAH was noted at all utilized dosages of the drug from the time of the first urine collection period after drug administration until termination of the study.
In two of the subjects, S. Figure 3 . All showed definite inhibition of sodium and chloride excretion, during drug administration which persisted for three days after discontinuance of medication. Thus, in subject 0. G., the mean sodium excretion fell from a control value of 0.81 Gm. per day to 0.37 Gm. per day during medication, rising to 0.61 Gm Significant changes in plasma potassium, in-orally, 0.2 Gm. three times a day, to three suborganic phosphate and chloride concentrations jects during effective probenecid uricosuria (1.0 were not noted in any of the three subjects.
Gm. probenecid per day) resulted in a moderate The effect of simultaneous administration of depression of the 24-hour urate excretion for one phenylbutazone and probenecid (Benemid) upon or two days. This was followed by return to preurinary urate excretion was studied in seven sub-vious levels of urate excretion in spite of conjects. The administration of phenylbutazone tinued simultaneous administration of both drugs. In four subjects the acute effects of concomitant intravenous administration of both drugs upon inulin and urate clearances were determined by giving 1 Gm. of probenecid prior to phenylbutazone in two of the subjects, and subsequent to phenylbutazone in the remaining two. The results are presented in Table IV . Subjects P. C. and I. G. received intravenous probenecid first.
Their C urate/C1. ratios rose from 6.19 and 7.38 to 22.9 and 22.9, respectively, without any changes in C,.. When phenylbutazone was then administered, slight depressions in C,, occurred. The slight declines noted in C urate/C1n may be explained on the basis of the time required for the experimental procedure, the peak uricosuric effect of probenecid having subsided. In subjects C. G. and P. M., the prior administration of phenylbutazone resulted in a slight decline of C,. in P. M. only, and a slight elevation of C urate/C1. in both. Subsequent probenecid administration resulted in additional elevations of these ratios without further changes in Ci.. Marked interference with probenecid uricosuria by phenylbutazone administration is not apparent from these studies.
Untoward effects attributable to phenylbutazone administration were not observed in any of the subjects included in this study.
DISCUSSION

Uricosurk effect
Phenylbutazone in adequate dosage increased the urate clearance and enhanced urinary urate excretion in most gouty subjects studied. The uricosuric effect, in general, appeared to be related to the plasma phenylbutazone concentration. In the patients studied a plasma phenylbutazone concentration of approximately 10 mg. per cent was required to induce uricosuria and the uricosuric effects increased roughly in proportion to further elevation of drug levels in the blood. Immediate uricosuric plasma concentrations are readily achieved by intravenous injection of adequate doses. Thus, in three subjects, given 2.0 Gm. of phenylbutazone intravenously, the initial plasma drug levels five minutes after injection averaged 20 mg. per cent and were still as high as 14 mg. per cent 20 hours later. In most subjects receiving the usual daily dose, 0.8 Gm. by mouth, the plasma concentration of the drug, while variable from individual to individual, (6) usually ranges from 6 mg. to 15 mg. per cent.
For example, in subject M. H. (Table III) , who received this dosage daily by mouth, the plasma concentrations of phenylbutazone were found to be 6.9, 10.6, 14.4, and 15.2 mg. per cent on the four successive days of administration. Uricosuria started on the second day of medication, when the plasma phenylbutazone concentration was 10.6 mg. per cent, and became more marked as the plasma drug levels rose.
The data indicate that the uricosuric effect of phenylbutazone is attributable to inhibition of tubular reabsorption of filtered urate. C urate/ Ci. was found to be consistently and significantly elevated by the drug in adequate plasma concentration. The plasma urate in gout is virtually completely filtrable at the glomerulus, so far as we have been able to determine by ultrafiltration studies to be reported in detail elsewhere.
The observations of Burns and his associates (6, 7, 8) on the disposition of phenylbutazone in man appear to shed some light on the relationship between plasma phenylbutazone concentration and inhibition of tubular reabsorption of urate. These investigators found that, at plasma phenylbutazone concentrations less than 10 mg. per cent, the drug is almost completely bound to plasma proteins; at levels of 10 mg. per cent only 2 per cent of the drug is filtrable and, as the plasma concentration rises, more and more of the drug is filtrable. Since very little unmetabolized phenylbutazone is found in the urine (7), the freely filtrable fraction of the drug must be practically completely reabsorbed by the renal tubules. This reabsorptive process may interfere in some way with the transfer mechanisms for urate reabsorption.
The inhibition of tubular reabsorption of urate by phenylbutazone appears to be significantly less than that of comparable doses of probenecid. Thus in acute experiments with probenecid (4), doses of 20 mg. per Kg. body weight produced a mean rise in C urate from a control of 8.55 cc. per min. to 32.9 cc. per min., and a rise in C urate/C1. from a mean control value of 7.10 to 33.7. Under the same experimental conditions, phenylbutazone in doses greater than 20 mg. per Kg. body weight produced much lower peak responses (Table I) .
Because of the more pronounced and regular uricosuric effect of probenecid, and its insignificant predisposition to serious toxic reactions, probenecid is more suitable for protracted use as a uricosuric agent in chronic gout than phenylbutazone, which is not recommended for the purpose. Phenylbutazone may be employed to advantage in short-term therapy to control acute gouty seizures in many cases, however, since this action of the drug does not depend upon its uricosuric effect (1, 2).
Fall in plasma urate concentration and its relationship to uricosuria
In accordance with the general experience, we find that phenylbutazone in adequate dosage effects a significant fall in plasma urate levels. The question has been raised whether such declines can reasonably be accounted for by the concomitant increase, if any, in urinary urate excretion. Kidd, Boyce, and Freyberg (9), for example, noted a distinct decrease in plasma urate 'in 15 gouty subjects receiving 400 to 800 mg. phenylbutazone per day, but in nine of these patients, apparently on uncontrolled diets, they were unable to demonstrate a significant increase in urinary urate excretion.
Any attempt to relate changes in plasma urate concentration to the quantity of urate excreted in the urine is, for the present, subject to large error since this relationship is markedly affected by such variables as the size of the readily mobilizable tissue deposits (miscible pool) of urate in individual gouty subjects, fluctuations in urate biosynthesis due to intrinsic and extrinsic (dietary) causes, alterations in plasma volume, variations in renal clearance of urate, etc. If the readily mobilizable tissue deposit of urate is very small, or has been markedly depleted by prior treatment with a uricosuric agent, exhibition of any uricosuric drug will elicit only a small and transitory increase in urinary urate excretion and this will be accompanied by a distinct and sustained fall in plasma urate levels, reflecting the failure of replenishment from mobilizable tissue (tophaceous) reserves. This has been our invariable experience with probenecid and the observations on Case R. R. in the present study (Table III) would suggest that the same applies to phenylbutazone.
In our patients receiving phenylbutazone intravenously, the fall in plasma urate concentra-
